CorMedix Inc
CRMD
View Detailed Chart
10.610USD
+0.070+0.66%
Close 10/15, 16:00（ET）Quotes delayed by 15 min
791.73MMarket Cap
15.48P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+0.66%
5 Days
-5.86%
1 Month
-16.13%
6 Months
+43.38%
Year to Date
+30.99%
1 Year
+5.15%
View Detailed Chart
TradingKey Stock Score of CorMedix Inc
Currency: USD Updated: 2025-10-15Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
CorMedix Inc's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
7
analysts
Buy
Current Rating
20.500
Target Price
+94.50%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
CorMedix Inc Highlights
StrengthsRisks
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 66363.08% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 43.47M.
Overvalued
The company’s latest PE is 13.26, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 35.12M shares, increasing 10.55% quarter-over-quarter.
Held by John Hussman
Star Investor John Hussman holds 63.00K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 2.50.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
CorMedix Inc Info
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.
Ticker SymbolCRMD
CompanyCorMedix Inc
CEOMr. Joseph Todisco
Websitehttps://cormedix.com/
Related Instruments
+1.75%
+0.17%
-1.27%
-0.34%
-0.22%
-0.70%
+0.11%
+1.18%
-0.15%
-0.53%
-0.53%
-1.05%
+1.28%
-0.84%
-0.43%
+0.22%
0.00%
-0.93%
+0.19%
+0.67%Popular Symbols
